A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects


About this study

The purpose of this two-phase study is to compare CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.

The primary objective of Phase 2 is to determine confirmed objective response rate (ORR) for treatment with first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma. 

The primary objective of Phase 3 is to evaluate progression-free survival (PFS) for subjects receiving first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy for unresectable or metastatic melanoma.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Histologically or cytologically confirmed unresectable Stage III or Stage IV melanoma per AJCC Cancer Staging Manual Eighth Edition.
  • Measurable disease, as defined by RECIST v1.1 and both of the following:
    • At least 1 accessible lesion amenable to repeated IT injection;
    • One or more measurable lesions at least 1 cm in diameter that are not intended for CMP-001 injection and can be followed as target lesions per RECIST v1.1.
  • Able to provide tissue from a core or excisional biopsy (fine needle aspirate is not sufficient). A newly obtained biopsy (within 90 days before the first dose of study treatment) is preferred, but an archival sample is acceptable if no intervening therapy for melanoma/cancer was received.
    • Note: for tissue sampling details, please refer to the Laboratory Manual.
  • Adequate organ function based on most recent laboratory values within 3 weeks before the first dose of study treatment on Week 1 Day 1 (W1D1):
    • Bone marrow function:
      • Neutrophil count ≥ 1500/mm^3;
      • Platelet count ≥ 100 000/mm^3;
      • Hemoglobin concentration ≥ 9 g/dL;
      • White blood cells ≥ 2000/mm^3.
    • Liver function:
      • Total bilirubin ≤1.5 × the upper limit of normal (ULN) with the following exception: subjects with Gilbert Disease total serum bilirubin ≤ 3 × ULN;
      • Aspartate aminotransferase and alanine aminotransferase ≤ 3 ×ULN.
    • Lactate dehydrogenase ≤ 2 × ULN.
    • Renal function:
      • Estimated (Cockcroft-Gault) or measured creatinine clearance ≥ 30 mL/min.
    • Coagulation:
      • International normalized ratio or prothrombin time (PT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants;
      • Activated partial thromboplastin time or PTT ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
  • Eastern Cooperative Oncology Group Performance Status of 0 to 1 at Screening.
  • Age ≥18 years at time of consent.
  • Capable of understanding and complying with protocol requirements.
  •  Women of childbearing potential must have negative serum pregnancy test prior to dosing at W1D1 and be willing to use an adequate method of contraception from the time of consent until at least 150 days after the last dose of study treatment.
  • Male subjects must be surgically sterile or must agree to use adequate method of contraception from the time of consent until at least 210 days after the last dose of study treatment.
  • Able and willing to provide written informed consent and to follow study instructions. Subjects unable to provide written informed consent on their own behalf will not be eligible for the study.

Exclusion Criteria:

  • Uveal, acral, or mucosal melanoma.
  • Received prior systemic treatment for melanoma in the unresectable or metastatic setting. Prior adjuvant therapy is acceptable if the treatment course (of approximately 1 year duration) was completed and there was no recurrence within 6 months of the last dose of adjuvant treatment.
  • Received prior therapy with CMP-001.
  • Requires systemic pharmacologic doses of corticosteroids greater than the equivalent of 10 mg/day prednisone within 30 days before the first dose of study treatment on W1D1:
    • Subjects who are currently receiving steroids at a prednisone-equivalent dose of ≤10 mg/day do not need to discontinue steroids prior to enrollment;
    • Replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.
  • History of CTCAE v5.0 Grade 4 immune-related AE due to adjuvant CTLA-4 or PD-1 blocking antibody.
  • Not fully recovered from adverse events (to Grade 1 or less [per CTCAE v5.0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment.
  • Active pneumonitis, history of pneumonitis that required steroids, or history of interstitial lung disease.
  • Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to poorly controlled hypertension, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association Class II or greater), pericarditis within the previous 6 months, cerebrovascular accident, and implanted or continuous use of a pacemaker or defibrillator.
  • Known history of immunodeficiency.
  • Known additional malignancy that has progressed or required active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, curatively treated localized prostate cancer with prostate-specific antigen level below 4.0 ng/mL, in situ cervical cancer on biopsy or a squamous intraepithelial lesion on Papanicolaou smear, thyroid cancer (except anaplastic), and adjuvant hormonal therapy for breast cancer >3 years from curative-intent surgical resection.
  • Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment.
  • Untreated, symptomatic, or enlarging central nervous system metastases or carcinomatous meningitis (including leptomeningeal metastases from solid tumors).
  • Prior allogenic tissue/solid organ transplant.
  • Known or suspected active infection with severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2).
  • Active infection requiring systemic therapy. 16. Known or suspected infection with HIV, hepatitis B virus, or hepatitis C virus; testing is not required unless suspected.
  • Received a live/attenuated virus vaccination within 30 days prior to the first dose of study treatment on W1D1.
  • Received blood products (including platelets or red blood cells) or colony stimulating factors (including granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, or recombinant erythropoietin) within 30 days prior to the start of Screening.
  • History of allergy or hypersensitivity to nivolumab and/or any of its excipients.
  • Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator, would make the subject unable to cooperate or participate in the trial.
  • Participation in another clinical study of an investigational anticancer therapy or device within 30 days before the first dose of study treatment on W1D1.
    • Note: Participation in the follow-up phase (receiving no study treatment) of a prior study is allowed.
  • Requires prohibited treatment (i.e., non-protocol specified anticancer pharmacotherapy, surgery, or radiotherapy) for treatment of malignant tumor.
  • Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating Investigator.
  • Pregnant or breast-feeding or expecting to conceive or donate eggs or father children or donate sperm within the projected duration of the study, from the time of consent until at least 150 days after the last dose of study treatment for women and 210 days after the last dose of study treatment for men.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mahesh Seetharam, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer